BAL Pharma Consulting, Limited Liability Company
Clients
U.S. Private Late Development Stage Biotech Client in the Clostridium Difficile Space was Acquired By a Global Multi-National Firm for Undisclosed Terms.
Identified Potential Development and Commercialization Partners
Supported Development of Business Case for Partnering of Asset
.
Client Base
US and European, Private and Public Market Capitalization ranging from $50MM to $15Billion, VCs, Specialty Pharma, Pharma Commercial Service Organizations
Client Case Studies
European based private biotech client successfully out-licensed anti-bacterial receiving in excess of $20 million upfront payment from partner for a 1 year exclusive option to acquire U.S. rights to compound
U.S. based private acute therapy start-up client successfully attained orphan status from the FDA for reformulated IV therapy
Public global specialty pharma client with market capitalization in excess of $10Billion invested in an extensive market development plan, including commercial and medical initiatives to raise awareness of unmet needs and prepare the market for commercialization of two oral products.
Public U.S. biotech client with market capitalization of $250MM out-licensed development and commercialization rights of a phase 2 asset, realizing a significant upfront payment from the in-licenser.
European based private biotech out-licensed phase 2 ulcerative colitis compound to a large public multi-national company receiving upfront payment, and a future royalty stream on based on achievement of development milestones and commercial revenue.